m+Medelevator.RU
← Поиск публикаций
Cell reports · 2026

In situ multi-modal characterization of pancreatic cancer reveals tumor cell identity as a defining factor of the surrounding microenvironment.

СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Lyubetskaya Anna, Rabe Brian, Kavran Andrew, Bai Yulong, Fisher Andrew, Font-Tello Alba, Lewin Anne, Pliner Hannah, Fan Yunfan, Giampapa Lauren, Cheng Yelena, Dai Chao, Hu Ruifeng, Lila Tom, Alloy Alexandre P, Mason Mike, Brett Constance, Brett Todd, Seifuddin Fayaz, Vasquez Grinnell Steven, Stahlschmidt Soren R, Zhao Yilin, Golhar Ryan, Neuhaus Isaac, Carrera Daniel, Rios Carlos, Kar Pradeep, Shukla Abhishek, Bashford-Rogers Rachael, Meyer Matthew J, Abu Shah Enas, Heij Lara, Sivakumar Shivan, Trillo-Tinoco Jimena, Chen Benjamin J, Mavrakis Konstantinos J, Drokhlyansky Eugene

Аннотация

Pancreatic ductal adenocarcinoma is heterogeneous, with low tumor purity, a prominent microenvironment, and complex architecture, which preclude the identification of shared tumor-intrinsic and stromal biology within and across patients. We overcame these challenges by achieving necessary resolution and context through the application of complementary genomics, pathology, and machine-learning approaches to characterize primary untreated tumors from 39 patients. We captured 340,000 spatial low-bulk and 530,000 spatial single-cell transcriptomes and observed a spectrum of classical-to-basal tumor subtypes present within all patients. We found that each subtype has distinct regulators, stromal neighborhoods, microenvironment, extracellular matrix, and histology corresponding to multiple immunosuppressive and therapy resistance mechanisms. We defined key tumor heterogeneity features, including the presence of mixed KRAS mutations and tertiary lymphoid structures, identifying biomarkers that distinguish the latter from lymph nodes. Lastly, by leveraging patient, cell, and mouse data, we determined which aspects of tumor biology are recapitulated in bulk datasets and reductionist models.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты